|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C; B
|
|
INDICATIONS:
|
|
Herpes genitalis |
|
Herpes labialis |
|
Herpes simplex encephalitis |
|
Herpes zoster |
|
Infection, herpes simplex |
|
Infection, varicella- zoster |
|
Varicella |
| |
|
|
SIDE EFFECTS:
|
|
Anaphylaxis |
|
confusion |
|
elevated liver function tests |
|
fever |
|
hallucinations |
|
leukopenia |
|
lymphadenopathy |
|
peripheral edema |
|
seizures |
|
skin reactions, such as erythema multiforme, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, or urticaria |
|
visual abnormalities |
|
Malaise |
|
Gastrointestinal disturbances |
|
headache |
|
lightheadedness |
|
Agitation |
|
alopecia |
|
dizziness |
|
myalgia |
|
paresthesia |
|
somnolence |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Dehydration |
|
>> Renal function impairment, pre-existing |
|
Hypersensitivity to acyclovir, ganciclovir, or valacyclovir |
|
Neurological abnormalities |
|
Prior neurologic reactions to cytotoxic medications |
|
|
ADULT DOSE:
|
|
Genital herpes infection-Initial episode: Oral, 200 mg every four hours while awake, five times a day, for ten days .
Recurrent infections, intermittent therapy (< 6 episodes per year): Oral, 200 mg every four hours while awake, five times a day, for five days .
Recurrent infections, chronic suppressive therapy (³ 6 episodes per year): Oral, 400 mg twice a day, or 200 mg three to five times a day, for up to twelve months .
[Herpes simplex, mucocutaneous (treatment)] -Oral, 200 to 400 mg five times a day for ten days in immunocompromised patients .
[Herpes simplex, mucocutaneous (prophylaxis)] -Oral, 400 mg every twelve hours .
Herpes zoster (shingles)-Oral, 800 mg every four hours while awake, five times a day, for seven to ten days .
Varicella (chickenpox)-Oral, 800 mg four times a day for five days. Treatment should be initiated at the earliest sign or symptom of chickenpox.
Note: Adults with acute or chronic renal impairment may require a reduction in dose as follows :
Normal dosing regimen Creatinine clearance (mL Adjusted dosing regimen
/min)/(mL/sec)
200 mg every 4 hours, 5 > 10/0.17 200 mg every 4 hours, 5 times
times daily while awake daily while awake
0-10/0-0.17 200 mg every 12 hours
400 mg every 12 hours > 10/0.17 400 mg every 12 hours
0-10/0-0.17 200 mg every 12 hours
800 mg every 4 hours, 5 > 25/0.42 800 mg every 4 hours, 5 times
times daily while awake daily while awake
10-25/0.17-0.42 800 mg every 8 hours
0-10/0-0.17 800 mg every 12 hours
Hemodialysis patients: A dose should be administered after each dialysis session . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Varicella (chickenpox)-Children up to 2 years of age: Safety and efficacy have not been established .
However, no unusual toxicity or pediatrics-specific problems have been observed in studies done in children given 3000 mg per square meter of body surface area per day or 80 mg per kg of body weight per day .
Children 2 to 12 years of age, up to 40 kg of body weight: Oral, 20 mg per kg of body weight, up to 800 mg per dose, four times a day for five days .
Treatment should be initiated at the earliest sign or symptom of chickenpox .
Children 2 to 12 years of age, 40 kg of body weight and over: See Usual adult and adolescent dose . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|